Brief: Idera Pharmaceuticals Announces Initiation Of Illuminate-206 Trial Evaluating Tilsotolimod In Combination With Nivolumab And Ipilimumab For Treatment Of Solid Tumors
30/09/2019 12:42
Sept 30 (Reuters) - Idera Pharmaceuticals Inc IDRA.O :
* IDERA PHARMACEUTICALS ANNOUNCES INITIATION OF THE
ILLUMINATE-206
TRIAL EVALUATING TILSOTOLIMOD IN COMBINATION WITH NIVOLUMAB AND
IPILIMUMAB FOR THE TREATMENT OF SOLID TUMORS
Source text for Eikon: ID:nGNX9ySGg6
Further company coverage: IDRA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aceragen
See all newsBrief: Aceragen CEO John Taylor's Employment With Co Terminated
Brief: Aceragen Inc To Delist From The Nasdaq Stock Market
Aceragen Inc expected to post a loss of $1.20 a share - Earnings Preview
Brief: Aceragen Board Determined It Is In Best Interests Of Co,To Effect Transfer,Assignment Of All Of Co's Assets To Assignee
Aceragen Inc reports results for the quarter ended in March - Earnings Summary